We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

02.25.16   How does one achieve a strong communicative relationship with one’s doctor?

In this week's video, Dr. Brian Durie discusses how to develop a strong communicative relationship with your doctor.

Bottom line:

Make sure you find a doctor with a communication style that suits your needs. 


02.18.16   What are the key, ongoing clinical trials for myeloma patients?

In this week's video, Dr. Brian Durie answers what are the key, ongoing clinical trials for myeloma patients.

Bottom line:

Check clinicaltrials.gov or call the IMF for updates.


02.04.16   What are the best scans to monitor myeloma?

In this week's ask video, Dr. Brian Durie discusses what are the best scans to monitor myeloma and how it will be used for treatment.

Bottom Line:

MRI, PET scanning, and CT are the way forward for myeloma imaging tests.


01.28.16   Can myeloma progress after an autologous stem cell transplant (ASCT)?

In this week's video, Dr. Brian Durie the pros and cons of an autologous stem cell transplant (ASCT).

Bottom Line:

It is rare to become worse after ASCT, and its likely benefits need to be evaluated on a long-term basis.


01.21.16   Will any of the newly FDA-approved drugs be available for frontline therapy?

In this week's video, Dr. Brian Durie discusses if the newly FDA-approved drugs (Ninlaro, Emplicity, Darzalex) be available for frontline therapy?

Bottom Line:

When to use the new drugs requires a case-by-case discussion, with possible use in early disease stages.


01.14.16   What Should we know about FDA approval of Empliciti® (elotuzumab)?

In this week's video, Dr. Brian Durie discusses what patients and caregivers need to know on the recent approval of Empliciti® (elotuzumab).

Bottom Line:

Empliciti is a useful drug when used in combination with Rev/dex in a relapse setting.


01.07.16   What should we know about the FDA approval of Ninlaro® (ixazomib)?

In this week's video, Dr. Brian Durie discusses the recently FDA approved drug Ninlaro® (ixazomib).

Bottom Line:

Ninlaro is an important addition to the lineup of myeloma treatments.


12.17.15   What should we know about FDA approval of Darzalex® (daratumumab)?

In this week's video, Dr. Brian Durie discusses the first monoclonal antibody approved for myeloma treatment - Darzalex (daratumumab). 

Bottom  Line:

Darzalex is a useful drug that has some drawbacks in terms of testing


11.12.15   What is Ixazomib?

In this week's video, Dr. Brian Durie the new oral proteasome inhibitor ixazomib.

Bottom Line:
It will be very good for patients if ixazomib is as valuable as currently available drugs


11.05.15   Can DDT exposure cause myeloma?

In this week's video, Dr. Brian Durie answers the question if the insecticide DDT can cause myeloma?

Bottom Line:

We need to understand better how to prevent toxic exposure as another means of preventing myeloma


previous     next      view all